New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Cytokinetics, Inc (NASDAQ:CYTK), Rambus Inc (NASDAQ:RMBS), BioScrip Inc (NASDAQ:BIOS), Rentech, Inc (NASDAQ:RTK)
Cytokinetics, Inc (NASDAQ:CYTK) showed a volume of 1.57 million shares by the end of last trade whereas the average volume of the stock remained 441,374.00 shares. The stock opened the session at $8.44 but then moved to $9.58. At that price, the stock showed a positive performance of 14.73%. Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company’s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart.
Will CYTK Continue To Move Higher? Find Out Here
Rambus Inc (NASDAQ:RMBS) opened the session at $8.71 and closed the session at $8.69. The stock showed a negative performance of -0.57% in previous trading session. Traded with volume of 1.56 million shares in the prior session and the average volume of the stock remained 1.35 million shares. Rambus Inc. (Rambus) is a technology solutions company. The Company invents, develops, offers and licenses solutions that challenge and enable its customers to create the future. It also develops products and services in security, advanced LED lighting and displays, and immersive mobile media. The Company has four business units: Memory and Interfaces Division, or MID, which focuses on the design, development and licensing of technology that is related to memory and interfaces; Cryptography Research, Inc., or CRI,
Has RMBS Found The Bottom And Ready To Gain Momentum? Find Out Here
BioScrip Inc (NASDAQ:BIOS) opened the session at $7.46 and closed the session at $7.52. The stock showed a positive performance of 7.46% in previous trading session. Traded with volume of 1.54 million shares in the prior session and the average volume of the stock remained 1.48 million shares. The beta of the stock remained 1.45. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services. Its platform provides service capabilities and the ability to deliver clinical management services, which offers patients a community-based and home-based care environment. Its core services are provided in coordination with, and under the direction of the patient’s physician. Its home health professionals,
Why Should Investors Buy BIOS After The Recent Gain? Just Go Here and Find Out
Rentech, Inc (NASDAQ:RTK) the stock advanced 0.54% and finished the session at $1.86. Traded with volume of 1.51 million shares in the prior session and the average volume of the stock remained 2.17 million shares. The beta of the stock remained 2.40. Rentech, Inc. (Rentech) is a provider of clean energy solutions. The Company owns and operates a nitrogen fertilizer plant in East Dubuque, Illinois, that manufactures and sells natural gas-based nitrogen fertilizer products within the corn-belt region in the United States. It is developing energy projects to produce certified synthetic fuels and electric power from carbon-containing materials, such as biomass, waste and fossil resources. Its technologies can produce synthesis gas (syngas) from biomass and waste materials,
Will RTK Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)